Cargando…

BRAF mutation and its inhibitors in sarcoma treatment

The mitogen‐activated protein kinase (MAPK) signaling pathway plays a significant role in mediating cellular physiological activities, such as proliferation, differentiation, apoptosis, and senescence. This signaling pathway is composed of several major proto‐oncogenes of RAS/RAF/MEK/ERK, among whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Haotian, Nazmun, Nahar, Hassan, Shafat, Liu, Xinyue, Yang, Jilong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367634/ https://www.ncbi.nlm.nih.gov/pubmed/32476297 http://dx.doi.org/10.1002/cam4.3103

Ejemplares similares

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries
por: Guha, Avirup, et al.
Publicado: (2021)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

AKT1 and BRAF mutations in pediatric aggressive fibromatosis
por: Meazza, Cristina, et al.
Publicado: (2016)

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma
por: Henke, Lauren E, et al.
Publicado: (2015)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
por: Bylsma, Lauren C., et al.
Publicado: (2019)

Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis
por: Berger, Mathilde, et al.
Publicado: (2020)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

BRAF(V600E) mutation test on fine‐needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients
por: Chen, Huang, et al.
Publicado: (2021)

An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting
por: Cowey, Charles L., et al.
Publicado: (2020)

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
por: Izar, Benjamin, et al.
Publicado: (2017)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Multicentric occurrence of multiple papillary thyroid carcinomas –HUMARA and BRAF mutation analysis
por: Nakazawa, Tadao, et al.
Publicado: (2015)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

BRAF(V600E) mutation analysis in fine‐needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false‐positive and false‐negative results
por: Zhao, Chong‐Ke, et al.
Publicado: (2019)

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
por: Gibney, Geoffrey T, et al.
Publicado: (2015)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

AGK‐BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma
por: Cordioli, Maria Isabel C. V., et al.
Publicado: (2016)

Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
por: Jain, Varsha, et al.
Publicado: (2019)

Hormonal therapy in uterine sarcomas
por: Zang, Yuqin, et al.
Publicado: (2019)

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review
por: Yu, Qingliang, et al.
Publicado: (2019)

BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases
por: Kobayashi, Shin, et al.
Publicado: (2021)

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)

Clinical outcomes of non‐osteogenic, non‐Ewing soft‐tissue sarcoma of bone––experience of the Toronto Sarcoma Program
por: Veitch, Zachary W., et al.
Publicado: (2020)

Multimodal MR imaging signatures to identify brain diffuse midline gliomas with H3 K27M mutation
por: Su, Xiaorui, et al.
Publicado: (2021)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF(V600E) oncoprotein kinase
por: van Veen, J Edward, et al.
Publicado: (2019)

BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer
por: Tan, Elaine, et al.
Publicado: (2022)

Identification of potential prognostic small nucleolar RNA biomarkers for predicting overall survival in patients with sarcoma
por: Liu, Jianwei, et al.
Publicado: (2020)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

Systemic treatments and outcomes in CIC ‐rearranged Sarcoma: A national multi‐centre clinicopathological series and literature review
por: Connolly, Elizabeth A., et al.
Publicado: (2022)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Outcomes of unplanned sarcoma excision: impact of residual disease
por: Charoenlap, Chris, et al.
Publicado: (2016)

Ewing’s Sarcoma of the Head and Neck: Margins are not just for surgeons
por: Bouaoud, Jebrane, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c1j5oius8gi1a0n621l6otgb1b